key: cord-0748588-d48a14zn
authors: Hu, Xinyu; Sun, Longyan; Guo, Zhaoyang; Wu, Chao; Yu, Xin; Li, Jie
title: Management of COVID-19 Patients with Chronic Liver Diseases and Liver Transplants
date: 2021-12-18
journal: Ann Hepatol
DOI: 10.1016/j.aohep.2021.100653
sha: 5b4d96f719055790235e18d00287da9971deae35
doc_id: 748588
cord_uid: d48a14zn

The epidemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has increasingly attracted worldwide concern. Liver damage or dysfunction occurred in patients with COVID-19 (mainly characterized by moderately elevated serum aspartate aminotransferase levels). However, it is not yet clear whether the COVID-19-related liver injury is mainly caused by the virus infection, potentially hepatotoxic drugs, or other coexisting conditions. Progression of pre-existing chronic liver disease (CLD) may be the underlying mechanism of liver injury. Although COVID-19 patients with CLD, such as nonalcoholic fatty liver disease, liver cirrhosis, and liver cancer, have been deemed at increased risk for serious illness in many studies, little is known about the impact of CLD on the natural history and outcome of COVID-19 patients. Thereby, based on the latest evidence from case reports and case series, this paper discusses the clinical manifestations, treatment, prognosis, and management of the COVID-19 patients with different CLD. This article also reviews the effect of COVID-19 on liver transplantation patients (LT), hoping to work for future prevention, management, and control measures of COVID-19. However, due to the lack of relevant research, most of them are still limited to the theoretical stage, further study of COVID-19 and CLD needs to be improved in the future.

The COVID-19 pandemic, resulting from the virus SARS-CoV-2, continues to cause significant morbidity and mortality worldwide. By early April 2021, more than 120 million COVID-19 confirmed patients and 2 million and 600 thousand related deaths have been accumulated worldwide since the first reported patient was diagnosed (1) .The main clinical characteristics of COVID-19 are fever and dry cough, while different degrees of liver damage have been observed in several patients with COVID-19 with gastrointestinal symptoms (2) .

Liver injury has been reported as a common manifestation with unclear clinical significance. The potential mechanisms of liver injury in COVID-19 include direct damage by the virus (based on the presence of the ACE2 receptor in the liver), psychological stress, systemic inflammatory response, drug-induced liver injury, and the progression of pre-existing liver diseases, i.e., from simple fatty liver to steatohepatitis (3) . Although COVID-19 patients with chronic liver disease (CLD) have been deemed to be at an increased risk for serious illness in many studies, little is known about the impact of CLD on the natural history and outcome of COVID-19.

Therefore, based on the existing evidence from case reports and case series, this article reviews the manifestations, treatment, prognosis, and management of COVID-19 patients with different CLDs in the clinic. This review also describes the influence of COVID-19 on liver transplantation patients to promote prevention, management, and control measures for COVID-19 in this patient population in the future.

Whether CLD patients are more likely to develop COVID-19 is unclear, as there is a dearth of data on the CLD prevalence among patients with COVID-19. A metaanalysis showed that the risk of COVID-19 did not increase in CLD patients.

However, it seems that patients with CLD were more likely to have severe or critical COVID-19 than those without CLD, and they were also more likely to have higher mortality (4) , and acute on chronic liver failure (ACLF) can also occur in patients with compensated CLD who had severe COVID-19(5) ( Table 1) . We summed all studies on COVID-19 with CLD patients in Table 2 .

The relationship between patients with chronic hepatitis B or C infection and liver injury caused by SARS-CoV-2 infection is not clear. There is no evidence to show that HBV patients infected with SARS-CoV-2 have different clinical manifestations or prognoses. Most HBV carriers infected with SARS-CoV-2 will not become severely or critically ill (6, 7) . The monocyte and white blood cell counts in SARS-CoV-2-infected patients with HBV were reported to be significantly lower than those in patients with SARS-CoV-2 infection alone, while the level of CD8-T cells was significantly higher, and SARS-CoV-2-infected patients with HBV consistently had a higher risk of thrombocytopenia (8) . Higher prothrombin times within the normal range in chronic HBV patients indicated a risk of abnormal coagulation (9) . However, due to the small sample size of the above studies, we cannot draw general conclusions. An Arabian patient developed severe liver injury with high levels of AST, ALT, and TB, suggesting that COVID-19 may cause HBV reactivation (10) . However, the causal relationship between liver injury and HBV reactivation remains unclear. Other reports also indicated the possibility of HBV reactivation during SARS-CoV-2 infection, but the risk seems low (11) . Accordingly, it is best to assess the viral load promptly if possible, or HBV infection can be treated with antiviral therapy for a short time during SARS-

Active HCV infection and HCV viral load seem to be related to poor prognosis (12) .

However, HCV antibodies may be suggestive of "protection" against COVID-19 because recently cured HCV patients were less likely to be infected with SARS-CoV-2 (13) .

The case of a 47-year-old male with HCV and past exposure to hepatitis B virus who developed severe COVID-19 pneumonia has also been reported. The administration of remdesivir resulted in a temporary lowering of the HCV viral load, followed by a significant rebound after its discontinuation with a hepatitis flare. A decrease in the anti-HBV titer was also noted, probably related to the administration of tocilizumab.

Thus, the treatment of SARS-CoV-2 infection in patients with chronic viral hepatitis requires close monitoring but does not necessarily preclude the use of antivirals such as remdesivir or immunosuppressors (14) .

Some HBV and HCV antiviral medications, such as sofosbuvir and tenofovir, may have therapeutic activity against SARS-CoV-2, but there is no current evidence of benefit, and the relevant clinical trials are still in progress. Medications could not be stopped for patients receiving anti-HBV therapy; therefore, the changes may be due to the immunological response to COVID-19 or an outbreak of HBV infection(15).

Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunctionassociated fatty liver disease (MAFLD) (16) , represents an increasing cause of liver disease (14) and is predicted to be present in the majority of COVID-19 patients with pre-existing CLD worldwide.

NAFLD patients are generally considered to have a longer viral shedding time, a higher possibility of liver dysfunction, and an increased risk of disease progression to severe COVID-19 than non-NAFLD patients (17) (18) (19) (20) . In a retrospective study of 202 consecutive patients with COVID-19 and MAFLD, liver injury occurred in 50% and 75.2% of patients on admission and during hospitalization, respectively. These findings may be attributed to the chronic inflammatory state of the liver in NAFLD patients. Additionally, the high expression of the ACE2 receptor was one of the possible reasons for liver injury based on an animal model of hepatic steatosis (21) . However, the relevant evidence is still not sufficient, and further research is needed.

NAFLD was indicated as an independent risk factor for COVID-19 progression (18, (21) (22) (23) . In addition, the liver fibrosis degree in NAFLD might influence the outcome of COVID-19; for example, the severity of COVID-19 illness was associated with intermediate or high FIB4 scores among patients with MAFLD (24) . MAFLD was associated with an approximately four times higher probability for severe disease (25) .

In NAFLD patients, the polarization status of hepatic macrophages, switching from inflammation-promoting M1 to inflammation-suppressing M2, was presumed to favor COVID-19 progression (18, 26) . The cytokine storm hypothesis suggests that fibrosis in the background of MAFLD may aggravate the severity of infection through the release of inflammatory cytokines in the liver (18) .

At present, except for several monoclonal antibody drugs that are still in clinical trials (27) , there is no specific drug for the treatment of COVID-19, and antiviral drugs and corresponding symptomatic therapy are the main treatments. However, the drugs seem to be more hepatotoxic and thus aggravate pre-existing steatosis through different proinflammatory factors in NAFLD patients. Proinflammatory cytokines, such as TNF-a, IL1-b, and IL-6, have been shown to significantly enhance the hepatotoxicity potential of various drugs, including antibiotics. Other pharmaceuticals, such as corticoids, antiretroviral agents, and methotrexate, might trigger the transition of simple fatty liver to NASH or worsen pre-existing steatosis, necroinflammation, and fibrosis (19) . There seems to be a vicious cycle between COVID-19 and NAFLD steatosis. The prevalence of NAFLD and the risk of patients with NAFLD progressing to severe COVID-19 highlight the significance of identifying and monitoring patients with liver diseases, especially those with metabolic disorders, during and after the COVID-19 crisis.

Alcohol intake may have become an uncontrollable condition due to the influence of relevant social and economic factors during the epidemic period, which may lead to adverse effects in alcohol-associated liver disease (ALD) patients. Few studies have mentioned the effect of COVID-19 on alcohol-associated liver disease patients.

Disorders of the innate and adaptive immune systems caused by alcohol may increase the risk of severe infection in patients with COVID-19. Common underlying medical conditions, including obesity with metabolic syndrome and chronic kidney disease, in ALD patients can also affect prognosis, acting as risk factors. The use of glucocorticoids in the treatment of alcoholic hepatitis patients should be more cautious during the COVID-19 pandemic, especially in high incidence areas. The follow-up of these patients also needs to be more proactive (15, 28) .

Despite some reports, the effect of immunosuppression on COVID-19 remains inconclusive. The immune function of autoimmune hepatitis (AIH) patients is passively suppressed, and their liver may be decompensated at the same time, which may have adverse effects on the recovery of COVID-19. Several large multicenter studies have found that COVID-19 patients seemed to have a similar disease process as the general patients among the patients who received immunosuppressive therapy, and immunosuppression may also reduce the risk of new-onset liver injury (29) (30) (31) .

Reducing immunosuppression in AIH (applicable to other autoimmune diseases) patients during the pandemic may be detrimental, as it may expose individuals to a higher risk of disease recurrence. In addition, immunosuppression may counteract the excessive inflammation driven by COVID-19. It was reported that if AIH patients suddenly reduce/stop immunosuppressive drugs during the stable period of disease, for most immunosuppressive drugs, these patients will have a high risk of recurrence (32) . According to APASL expert panel consensus recommendations, routine immunosuppressants and other therapeutic drugs should not be stopped for patients with autoimmune liver disease even if they are infected with SARS-CoV-2(33).

Since liver cirrhosis patients are often in a state of impaired immune function, these patients are susceptible to SARS-CoV-2 infection (34) . The overexpression of the ACE-2 enzyme in COVID-19 patients with decompensated cirrhosis may lead to an increase in SARS-CoV-2 viral titers (35) . In patients with cirrhosis, the ACE-2 reduction by SARS-CoV-2-induced internalization may aggravate liver fibrosis and portal hypertension and exacerbate disease severity.

Interestingly, COVID-19 patients with cirrhosis seem to have a different liver injury pattern. These patients usually had rapid and early worsening of jaundice, higher AST than ALT, and a low R-value, all of which were more pronounced in those who did not survive (36) . However, these findings still need to be confirmed. Lower platelet and lymphocyte counts, hypoproteinemia, and higher direct bilirubin levels, which are relatively more common manifestations in COVID-19 patients with liver cirrhosis than in COVID-19 patients without liver disease, might be indicators of a poor prognosis (37) (38) (39) . Evolving data from the global registry indicate a poor prognosis and higher mortality in cirrhosis patients (40) (41) (42) .

Considering the adverse effect of cirrhosis on COVID-19, management and treatment should be more stringent in terms of medication, monitoring, and follow-up. Remote management is necessary. Otherwise, the subtle differences between COVID-19 with cirrhosis caused by different etiologies and COVID-19 alone and the long-term effects of SARS-CoV-2 infection remain undefined. Furthermore, it is unclear whether COVID-19 patients with cirrhosis are affected by other complications associated with the novel coronavirus. Therefore, there are still many problems that need to be solved.

Available evidence suggests that patients with cancer seem to be more vulnerable to SARS-CoV-2 infection. In a systematic review, it was reported that the prevalence of COVID-19 in patients with previously diagnosed cancer was 2% (43) . There are few reports about hepatocellular carcinoma (HCC) in COVID-19 patients, and only a multicenter, observational cohort found that the all-cause mortality was 52.4% (n = 11) in their HCC subgroup, almost seven times that of patients without HCC (44) .

Even so, the data are insufficient to draw a definite conclusion. However, due to the close correlation between liver dysfunction and COVID-19, the low immune capability of these HCC patients, and the necessity of regular monitoring for tumor progression, liver cancer patients have become a vulnerable group that needs close attention.

In terms of treatment for this special group, a management guideline recommended that risk assessment and grading is a feasible method for HCC patients, and it is also recommended to lower the risk of SARS-CoV-2 infection during the convalescence of hospitalization by less invasive or noninvasive treatment (45) . Most HCC patients have cirrhosis and are thus afflicted with two comorbidities, which means that their liver immune function may not be favorable for the prognosis of COVID-19 (46) . 

Organ donation and transplantation are facing new challenges due to the global spread of COVID-19. Liver transplantation is the second most common solid-organ transplantation in the world, second only to kidney transplantation (50) . LT patients are often in a state of chronic immunosuppression, which can increase opportunistic infection. Therefore, the effect of COVID-19 on LT patients has attracted wide attention in the context of the pandemic.

In terms of clinical symptoms, the existing evidence shows that the clinical symptoms and signs of LT patients with COVID-19 are relatively atypical in contrast to the general population. Some cases reported that LT patients infected with SARS-CoV-2 had low-grade or no fever. However, LT patients seem to be affected by diarrhea complications more easily (51, 52) . Interestingly, it seems that patients with short-term transplantation have fewer symptoms of fever and dyspnea than long-term transplantation patients (53) . Therefore, the neglect of early infection in this group should be vigilant. Gastrointestinal symptoms were more common in the LT population (28.6%) but were similar to those in other solid-organ transplant cohorts (54) . More extensive damage manifestations on chest CT and lymphopenia in LT patients with COVID-19 were common, as well as elevated C-reactive protein and erythrocyte sedimentation rates (55, 56) . In addition, a review showed that LT patients with COVID-19 may have some unreported symptoms, including chest distress, pain, and jaundice (56) .

A systematic review, including available databases up to June 2020, showed that the COVID-19 case-fatality rate in LT patients was 19.3% (mean age=59.6 years), higher than the 8% mortality in the general population of a similar age, from 70 to 79 years (54) . However, another study in Spain found that the number of deaths observed in LT patients (mortality rate 18%) was slightly lower than expected after adjusting for age and sex, with a standardized mortality rate of 95.55 (95% CI: 94. 25-96.85) . In this study, the standardized incidence ratio was 206.48 (95% CI 205. 45-207.52) in the subset of patients older than 60 years (57) . A positive correlation between death and the length of time on immunosuppressants was reported from an Italian LT center. All deaths associated with COVID-19 were related to patients receiving minimal long-term immunosuppression after LT but not to recently transplanted, fully immunosuppressed patients (58) . Therefore, LT patients seem to be more vulnerable to SARS-CoV-2 due to the use of immunosuppressants, but there is no significant difference in case mortality between LT patients and the general population. More caution should be exercised in COVID-19 patients with long-term immunosuppression.

Although immunosuppressive drugs may attenuate the inflammatory response in the early stages of the disease, the increased risk of viral toxicity arrives concomitantly.

Previous data related to coronavirus infection (SARS-2003 and MERS) did not show a greater threat to mortality with the use of immunosuppressive drugs in LT patients (59) . Patients taking mycophenolate or discontinuing immunosuppression were more prone to develop severe COVID-19, while baseline therapy with a calcineurin inhibitor or everolimus had no statistical significance. The calcineurin inhibitor seemed to contribute to inhibiting virus replication. Therefore, it may be feasible to adjust mycophenolate drugs to calcineurin inhibitors or everolimus (57) .

The Beijing liver transplantation working conference pointed out that patients with severe or rapidly progressive COVID-19 can decrease the dose of calcineurin inhibitors and consider discontinuing antimetabolite drugs while taking antiviral therapy; dose reductions in patients with mild to moderate COVID-19 are not recommended, but relevant indicators should be well monitored. Glucocorticoids can be maintained at a low dose in cases of adrenal insufficiency (55) .

The presence of the virus may be hidden in immunosuppressed recipients, thus allowing them to carry the virus for a longer time, increasing the risk of contact transmission. A case report described a patient who turned positive after a negative viral test as an LT patient, which provides evidence of the presence of SARS-CoV-2 being hidden in these patients (60) . Relevant personnel, including health care workers, should be alert to this possibility for similar patients and take measures for selfprotection. However, a case report from Italy showed that LT between SARS-CoV-2infected (with antibody-positive) donors and recipients seemed to be feasible, which could potentially provide a life-saving opportunity for SARS-CoV-2-positive waitlisted patients (61) . According to the LTSI guidelines in India, as well as the AASLD Expert Panel Consensus Statement, the relevant indications for LT should be strictly observed during the COVID-19 pandemic, in addition to basic epidemic prevention measures. It is necessary to limit the patient's condition and consider telemedicine alternatives. Both donors and recipients are supposed to be tested for the virus before transplantation. There is no obvious evidence that the immunosuppressive regimen needs to be modified. Symptomatic patients with COVID-19 can appropriately reduce immunosuppressive drugs, and high-dose immunosuppression can be initiated only when acute rejection occurs. Postoperative follow-up should be carried out as much as possible (62, 63) .

At present, most COVID-19 patients can recover without special treatment, and clinical data on these drugs are limited, especially for CLD patients. Drugs for COVID-19 include antimalarials (chloroquine and hydroxychloroquine), antivirals (remdesivir, favipiravir, and lopinavir/ritonavir), convalescents, and some monoclonal antibody products. Both antimalarial and antiviral drugs have been reported to be associated with a risk of liver injury (19, 64) . The monoclonal antibody drugs discovered recently provide a new possibility for COVID-19 treatment (27) . In addition, COVID-19 patients usually have a fever, and many use acetaminophen, which is known to cause liver injury. Therefore, it seems that there is no optimal treatment plan for CLD patients infected with SARS-CoV-2. Antibody drugs may be appropriate, but there is also a lack of evidence. Regardless, it is necessary to monitor liver function during treatment and avoid a combination of multiple drugs as much as possible. Patients with liver cirrhosis (with or without HCC) have priority to be vaccinated owing to their mortality risk. This priority also applies to patients waiting for LT. (3) A third or even fourth vaccination is recommended for LT patients and patients with cirrhosis with low or no antibody titers. (4) Research on the scope and duration of vaccination protection for CLD patients still needs to be improved (Figure 1 ).

In general, limited information is available on the impact of SARS-CoV-2 infection in Currently, the uncertainties in the order of occurrence make it difficult to identify whether liver injury is a risk factor for or an outcome of COVID-19 progression from a bystander perspective. There is also the problem of missing data related to the underlying liver disease.

Guarantor of article: Jie Li, Xin Yu Study concept and study supervision: Jie Li, Xin Yu, Zhaoyang Guo Data collection and/or data interpretation: Xinyu Hu Manuscript drafting: Xinyu Hu, Longyan Sun, Jie Li Manuscript edition and final approval: All authors

The authors declare that they have no conflict of interest.

None. Table 1 . Impact of COVID-19 in the management of chronic liver disease patients

Chronic viral hepatitis 6, 9, 13 It is unknown if patients with chronicHBV/HCV infection are more vulnerable to liver damage from SARS-CoV-2, or whether these patients have a greater risk of severe disease after acquiring COVID-19 or not.

Treatment of SARS-CoV-2 in patients with chronic viral hepatitis requires close monitoring but does not necessarily preclude the use of antivirals such as remdesivir or immunosuppressors.

Non-alcoholic fatty liver disease (NAFLD) 16, [19] [20] [21] NAFLD isindicated as an independent risk factor for disease progression to severe COVID-19, highlights the significance of monitoring patients with metabolic disorders during the COVID-19 crisis.

Alcohol associated liver disease (ALD) 13, 25 The disorder of the innate and adaptive immune system caused by alcohol may increase the risk of severe infection in COVID-19 patients and the follow-up work of related patients need to be more proactive.

Autoimmune hepatitis (AIH) 27 No data suggests AIH patients, even if immunosuppressed, being at an increased risk of severe SARS-CoV-2 infection. Routine immunosuppressants and other therapeutic drugs should not be stopped or lower for AIH patients with COVID-19.

Cirrhosis [34] [35] [36] Evolving data indicate a poor prognosis and higher mortality in cirrhosis patients. Treatment and management of cirrhosis patients with COVID-19 should be more stringent in medication, monitoring, and follow-up.

Hepatocellular carcinoma (HCC) 38, 39 There is no data on the prognosis of COVID-19 in HCC patients.

Most of the patients present with two major diseases: cancer and concomitant CLD, they may have an increased risk of severe COVID-19. 

Prevalence, incidence, and outcome of nonalcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis

Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes

Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease

Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis

Effect of COVID-19 on patients with compensated chronic liver diseases

Clinical Features and Outcomes of Coronavirus Disease 2019 (COVID-19) Patients With Chronic Hepatitis B Virus Infection

Impact of COVID-19 in patients with concurrent co-infections: A systematic review and meta-analyses

Clinical characteristics of COVID-19 patients with hepatitis B virus infection -a retrospective study

A case series of COVID-19 patients with chronic hepatitis B virus infection

COVID-19-Induced Hepatic Injury: A Systematic Review and Meta-Analysis

Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy

Liver Impairment and Hematological Changes in Patients with Chronic Hepatitis C and COVID-19: A Retrospective Study after One Year of Pandemic

Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?

A Case of Severe Acute Respiratory Syndrome Coronavirus 2 Treatment With Remdesivir in a Hepatitis C-Coinfected Patient Resulting in Temporary Viral Control and Posttreatment Flare

WGO Guidance for the Care of Patients With COVID-19 and Liver Disease

International Consensus P. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

Clinical features of COVID-19 patients with non-alcoholic fatty liver disease

Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19

Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury

MAFLD in COVID-19 patients: an insidious enemy

Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis. Dig Liver Dis

NAFLD and COVID-19: a Pooled Analysis

COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics

Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores

Metabolic-associated fatty liver disease is associated with severity of COVID-19

Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

Chronic Liver Disease and COVID-19: Alcohol Use Disorder/Alcohol-Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis

Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study

SARS-CoV-2 infection in patients with autoimmune hepatitis

Behaviors, symptoms, and outcomes of North American patients with autoimmune hepatitis during the COVID-19 pandemic

Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients

Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations

Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis

ACE2: A Linkage for the Interplay Between COVID-19 and Decompensated Cirrhosis

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study

Clinically significant portal hypertension in cirrhosis patients with COVID-19: Clinical characteristics and outcomes

Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China

Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort

Poor outcomes in patients with cirrhosis and Corona Virus Disease-19

High rates of 30-day mortality in patients with cirrhosis and COVID-19

COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis

Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study

Guidelines Adaptation to the COVID-19 Outbreak for the Management of Hepatocellular Carcinoma

Management of Hepatocellular Carcinoma during the COVID-19 Pandemic -Sao Paulo Clinicas Liver Cancer Group Multidisciplinary Consensus Statement

Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission

APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19

Why is organ transplantation clinically important? Cold Spring Harb Perspect Med

COVID-19 and liver transplantation: Lessons learned from three reported cases

COVID-19 in a liver transplant recipient: Could iatrogenic immunosuppression have prevented severe pneumonia? A case report

COVID-19 in an international European liver transplant recipient cohort

Clinical Presentation, Treatment, and Mortality Rate in Liver Transplant Recipients With Coronavirus Disease 2019: A Systematic Review and Quantitative Analysis

Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation

Prognosis and Treatment of Liver Transplant Recipients in the COVID-19 Era: A Literature Review

Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients

Management of Patients with Liver Transplant and Chronic Liver Diseases During COVID-19 Pandemic: A Brief Review

Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic

Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient

Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor

Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI)

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients

Italian association for the study of the liver position statement on SARS-CoV2 vaccination

Figure 1. Current Suggestions for SARS-CoV-2 Vaccianation on CLD patient (Ab: antibody, NAFLD: non-alcoholic fatty liver disease, ALD: alcohol associated liver disease, HCC: hepatocellular carcinoma, LT: liver transplantation

Dr. Jie Li wishes to acknowledge the support from the National Natural Science Fund 

Patients would be treated with oral hydroxychloroquine and/or azithromycin for 5-7 days. In patients with moderate-severe COVID-19, antiviral therapy with lopinavir/ritonavir or remdesivir was allowed as compassionate use. Patients with acute distress respiratory syndrome could receive boluses of steroids and/or tocilizumab.